House Rx

Other Healthcare Technology Systems · San Francisco, CA · Founded 2021 · Privately Held (backing)

Operator of a technology-enabled service company intended to make specialty medication more accessible and affordable. House Rx is based in San Francisco, CA and was founded in 2021. It was valued at $253 million at its early-stage round in Nov 2025, the last priced event on record. It has raised $84.9 million across 1 recorded round; the latest was a $55 million Series B in Nov 2025.

PMV mark · valuation
$253.0M
Oct 2026
Priced at
its early-stage round
Nov 2025
Total raised
$84.9M
Last round
Early Stage VC (Series B)
Nov 2025

Who backs House Rx?

12 investors
InvestorType
Khosla VenturesVenture capital
Bessemer Venture PartnersGrowth equity
New Enterprise AssociatesVenture capital
First Round CapitalOther
Reform Ventures—
1984 VenturesVenture capital
Maverick VenturesHedge fund
Character (VC)Venture capital
Town Hall VenturesVenture capital
Cencora Ventures—
+ 2 more investors · a free account shows the complete list
The directory is free. Investor activity — the working column — is Pro.Unlock prospecting columns

Membership and data by Private Market View

House Rx investors

12 investors are on record for House Rx, including Khosla Ventures, Bessemer Venture Partners, New Enterprise Associates and First Round Capital. By type, the record holds 5 venture capital firms, 1 hedge fund and 1 growth equity firm. The Series B in Nov 2025 drew 6 investors.

Free account
More of House Rx with a free account
  • ·The complete investor list: 12 names
  • ·Watch House Rx: the Monday email on marks, rounds and moves
Create free account
No card required

Membership and data by Private Market View

For fundraisers
Work this list, don’t just read it

These 12 firms already write checks for companies like House Rx in other healthcare technology systems. Build the wider list: every firm that has backed a company like this one, ranked by how often and how recently.

Find investors like these →

Membership and data by Private Market View